WO2003064462A1 - Pth a liaison peg ou derive de pth a liaison peg - Google Patents
Pth a liaison peg ou derive de pth a liaison peg Download PDFInfo
- Publication number
- WO2003064462A1 WO2003064462A1 PCT/JP2003/001067 JP0301067W WO03064462A1 WO 2003064462 A1 WO2003064462 A1 WO 2003064462A1 JP 0301067 W JP0301067 W JP 0301067W WO 03064462 A1 WO03064462 A1 WO 03064462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pth
- peg
- bound
- derivative according
- cys
- Prior art date
Links
- 108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 241
- 239000000199 parathyroid hormone Substances 0.000 claims description 269
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 233
- 229960001319 parathyroid hormone Drugs 0.000 claims description 213
- 229920001223 polyethylene glycol Polymers 0.000 claims description 171
- 239000002202 Polyethylene glycol Substances 0.000 claims description 168
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 47
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 58
- 210000004369 blood Anatomy 0.000 description 50
- 239000008280 blood Substances 0.000 description 50
- 239000011575 calcium Substances 0.000 description 47
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 46
- 229910052791 calcium Inorganic materials 0.000 description 46
- 108010049264 Teriparatide Proteins 0.000 description 36
- 230000001965 increasing effect Effects 0.000 description 32
- 241000700159 Rattus Species 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 230000036772 blood pressure Effects 0.000 description 19
- 238000007920 subcutaneous administration Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 14
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 13
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 102000058004 human PTH Human genes 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000037182 bone density Effects 0.000 description 11
- 229920001427 mPEG Polymers 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- -1 for example Polymers 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- 230000004531 blood pressure lowering effect Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 230000003491 cAMP production Effects 0.000 description 8
- 238000005277 cation exchange chromatography Methods 0.000 description 8
- 210000004705 lumbosacral region Anatomy 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000008351 acetate buffer Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 208000037147 Hypercalcaemia Diseases 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000148 hypercalcaemia Effects 0.000 description 5
- 208000030915 hypercalcemia disease Diseases 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007981 phosphate-citrate buffer Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 3
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 102000051132 human PTH1R Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 2
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 2
- 101001084273 Rattus norvegicus Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101001135767 Rattus norvegicus Parathyroid hormone Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 108010053339 parathyroid hormone (1-11) Proteins 0.000 description 1
- 108700000288 parathyroid hormone (1-28) Proteins 0.000 description 1
- 108010073381 parathyroid hormone (1-37) Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Definitions
- the present invention relates to a PEG-conjugated parathyroid hormone (PTH) or a PEG-conjugated PTH derivative to which polyethylene glycol (PEG) is conjugated, a PEG-conjugated PTH composition containing these, a PTH preparation containing these as an active ingredient, and It concerns these manufacturing methods.
- PTH parathyroid hormone
- PEG polyethylene glycol
- Parathyroid hormone is a hormone that is mainly secreted from the parathyroid gland and controls blood calcium levels (Kronenberg, HM et al., Handbook of Experimental Pharmacology, Springer-Verlag, Heidelberg, Germany, ppl85-201, 1993) and is known as one of the important hormones in bone metabolism.
- PTH is secreted from the parathyroid gland when blood calcium levels decrease.
- PTH promotes calcium reabsorption in the kidneys and induces 25 vitamin D-1 hydroxylase to convert vitamin D to its active form.
- PTH also promotes calcium absorption from the intestinal tract via this activated vitamin D. In bone, it acts on osteoblasts to promote bone resorption.
- PTHrP Parathyroid hormone-related protein
- HMM Humoral hypercalcemia maliganncy
- PTH and PTH r P are known to act on the PTH 1 receptor (Juppner, H. et al, Science 254: 1024-1026, 1991).
- the PTH1 receptor binds to the same degree as PTH and PTHrP with the same level of binding, and increases PKA signals inside cells and activates PLC signals by increasing intracellular calcium concentration (Abou- Samra, AB, et al., Pro. Natl. Acad. Sci. USA, 89: 2732-2736, 1992; Bringhurst, FR et al, Endocrinology 132: 2090-2098, 1993). It is well known that PTH is one of the essential systemic factors in bone remodeling.
- PTH blood pressure lowering
- PTH (1-34) has been reported to cause blood pressure lowering in rats and dogs
- the blood pressure lowering effect of PTH analog has also been studied, and PTH (1-34) shows a strong blood pressure lowering effect when administered subcutaneously (Whitfield, JF et al, Calcif Tissue Int, 60: 302-308). , 1997).
- intravenous administration of PTH (1-34) has been reported to have a hypotensive effect, and transient headache has been reported after PTH administration (Igarashi, T. et al.
- a dose of 20 g has been determined to be a clinically usable dose (Neer, RM et al, New Engl J Med 19: 1434-1441, 2001).
- the guideline also permits the use of a dose one step below the dose that is unacceptable due to side effects as a clinical dose.
- subcutaneous administration of a drug has a lower bioavailability (BA) than intravenous administration.
- BA bioavailability
- PTH has the property of being rapidly absorbed and metabolized when administered subcutaneously (Fox, J. et al., Bone, 21: 163-169, 1997).
- WO 96/3 5447 discloses patch or iontophoresis of an infusion for continuous administration. It discloses a pharmaceutical dosage form of PTH in which the active ingredient is released for 2 to 6 hours by continuous transdermal administration.
- this dosage form has the following problems due to transdermal administration. In other words, patches are easy to use, but allergies and rashes to additives and adhesives for percutaneous absorption are apt to occur, which puts a heavy burden on patients, and the iontophoresis method requires large equipment. . In general, subcutaneous administration of a drug results in lower BA than intravenous administration.
- WO966Z35447 does not describe hypercalcemia or blood pressure lowering at all, and it is considered that this administration form has no effect of reducing side effects.
- sustained release is imparted by binding the Fc domain of an antibody to the activity-regulating domain of PTHZPTHrP.
- the onset of hypercalcemia is suppressed by simultaneous administration of a bone resorption inhibitor.
- single agent administration has shown a strong blood calcium concentration increasing effect even in normal mice, the blood calcium concentration increasing effect in clinical application is expected to be very strong, and is clinically useful. It is considered that there is no sex.
- JP-A-7-196925 discloses a method and composition for imparting desirable properties to protein by modifying a protein with a water-soluble polymer. ing. Specifically, a water-soluble polymer or oxylamine capable of forming a hydrazone bond or an oxime bond with an aldehyde group, a ketone group, lactol, an activated carboxylic acid or an activated carboxylic acid derivative on a protein. It describes proteins that have been modified by covalent attachment to a derivative of a water-soluble polymer (eg, PEG).
- a water-soluble polymer or oxylamine capable of forming a hydrazone bond or an oxime bond with an aldehyde group, a ketone group, lactol, an activated carboxylic acid or an activated carboxylic acid derivative on a protein. It describes proteins that have been modified by covalent attachment to a derivative of a water-soluble polymer (eg, PEG).
- modified proteins have increased solubility in aqueous solutions, increased stability during storage, reduced immunogenicity, increased resistance to enzymatic degradation, and increased compatibility with a wider variety of drug delivery systems. Properties such as compatibility and increased in vivo half-life are conferred.
- a water-soluble polymer for example, PEG, binds to various free groups of amino acids or sugars constituting proteins or glycoproteins, and forms 6 to 34 PEGs per molecule of protein. (Molecular weight of 2,000 to 12,000), which gives the above-mentioned new properties for the first time.
- PEG I NTRON Schering-Brow
- PEG AS YS Hoffman La Roche
- PEG AS YS Hoffman La Roche
- the present inventors conducted various studies in order to solve the above problems.
- PEG polyethylene glycol
- the blood concentration of PTH was sustained compared to PTH without PEG, while a significantly higher BA was obtained by subcutaneous administration. And found that it significantly reduced blood pressure drop.
- the present invention has found that there is no rapid increase in blood calcium concentration by selecting the PEG chain length to be bound to PTH within a range that is usually judged to be rather short for enhancing drug efficacy. And showed that it is possible to control the side effects.
- the present invention has been completed based on these findings.
- an object of the present invention is to provide a PTH which can obtain a high BA upon subcutaneous administration and has few side effects.
- the present invention provides a PEG-bound PTH or a PEG-bound PTH derivative to which PEG is bound.
- the present invention also provides a PEG-bound PTH composition containing the PEG-bound PTH or the PEG-bound PTH derivative.
- the present invention provides a PTH preparation containing, as an active ingredient, the above-mentioned PEG-bound PTH or PEG-bound PTH derivative in an effective amount for maintaining the efficacy.
- the present invention also provides a [Cys] -PTH derivative in which a cysteine residue has been introduced into PTH or a PTH derivative.
- the present invention provides a method for producing the above PEG-bound PTH or PEG-bound PTH derivative, which comprises condensing an amino group in PTH or the PTH derivative with a PEG derivative, or adding a PEG derivative to an amino group.
- a method for producing the above PEG-bound PTH or PEG-bound PTH derivative which comprises condensing an amino group in PTH or the PTH derivative with a PEG derivative, or adding a PEG derivative to an amino group.
- FIG. 1 (a) is a silver-stained electrophoresis photograph obtained by performing SDS-PAGE on 5k and 20k PEG-PTH using PhastGel Homogeneous 20. (B) is 2k
- FIG. 2 shows SDS-P for 5k PEG-PTH using PhastGel Homogeneous 20.
- FIG. 3 is a graph showing changes in plasma concentrations of PTH (1-34) and PEG-PTH (1-34) by intravenous administration.
- FIG. 4 is a graph showing changes in plasma concentrations of PTH (1-34) and PEG-PTH (1-34) by subcutaneous administration.
- FIG. 5 is a graph showing the time course of the corrected blood ionized calcium concentration when normal mice were administered with hPTH (1-34), 5k and 2k PEG-PTH (1-34).
- FIG. 6 is a graph showing the time course of blood pressure up to 20 minutes after administration of PTH to rats.
- FIG. 7 is a graph showing the difference between the mean blood pressure value before administration of PTH and the value showing a decrease in systolic blood pressure after administration as an average soil error.
- Figure 8 shows the effect of increasing the lumbar spine bone density by administration of hPTH (1-34), [Cys 35 ] -hPTH (1-35) and 2k PEG- [Cys 35 ] -PTH (1-35) in ovariectomized rats. It is a graph which shows (a) and the femur bone density increasing effect (b).
- the present invention relates to PEG-conjugated parathyroid hormone (PTH)
- the PTH in the present invention includes natural PTH, recombinant PTH produced by genetic engineering techniques, and chemically synthesized PTH.
- examples include human PTH consisting of 84 amino acid residues (human PTH). (1-84)), especially recombinant human PTH (1-84) produced by genetic engineering techniques.
- PT The H derivative refers to the aforementioned PTH partial peptide, PTH itself or a partial amino acid of the partial peptide substituted with another amino acid, or PTH itself or a partial amino acid of the partial peptide deleted.
- PTH partial peptides include, for example, human PTH (1-9), human PTH (1-11), human PTH (1-14), human PTH (1-20), human PTH (1-28), human PTH (1-34), human PTH (1-35), human PTH (1-37), human PTH (1-38), human PTH (1-64), human PTH (35-84), ⁇ PTH (1-34).
- PTH (1-34) is a partial peptide of PTH consisting of 34 amino acids from the N-terminus to the 34th amino acid of PTH, or a product obtained by aminating its carboxy terminus (ie, human PTH (1-34) -NH 2 ).
- amino acid substitution include substitution of the constituent amino acid at position 8 with leucine or norleucine, substitution of the constituent amino acid at position 18 with leucine or norleucine, and substitution of the constituent amino acid at position 34 with tyrosine.
- PTH or a PTH derivative into which a cysteine residue is introduced that is, one or more amino acid residues of PTH or a PTH derivative are substituted with a cysteine residue, and / or one or more PTH or a PTH derivative [Cys] -PTH derivatives having a cysteine residue added or inserted can also be used.
- the site for introducing a cysteine residue is not particularly limited. Is introduced at a site other than the N-terminus, for example, introduced at positions 9 to C, 11 to (terminal, 14 to ⁇ , 20 to (terminal, or 28 to C Contact is, are specifically introduced at the C-terminus.
- cis-Ting residue at the C-terminus of PTH (1-34) [Cy s 35 ] Ru can be used-PTH (1 -35).
- introduction of a cysteine residue from the 9th position to the C terminus means substitution of any amino acid residue at the 9th position to the C terminus with a cysteine residue, between 9th and 10th positions to the C terminus.
- the purity of the PTH or PTH derivative used in the present invention does not necessarily have to be 100%, and these PTH or PTH derivative may be substantially pure.
- “substantially pure” refers to a substance that has been purified so as to show at least a single peak by HP LC, and is particularly single using a combination of techniques such as SDS-PAGE and capillary electrophoresis. Means that it was confirmed.
- Such PTHs can be obtained by the method described in JP-A-6-87897 (corresponding to U.S. Pat. No. 5,208,041) or disclosed in JP-T-4-1505259 (WO90Z).
- Production and confirmation can also be made using the method described in J. Biol. Chem., 265, 15854, 1990 or an improved method thereof.
- PEG can be bound by reacting a PEG derivative having an active ester at one end with a ⁇ or ⁇ derivative.
- the PEG derivative used in the present invention include those in which one end is methoxylated.
- a PEG derivative in which a non-methoxylated terminal is condensed with an amino group or a thiol group or a functional group which can be added thereto is introduced, for example, succinimidyl lower fatty acid ester PEG, aldehyde PEG, benzotriazole carbonated PEG, glycidyl etherified PEG, oxycarbonylimidazolated PEG, nitrophenylcarbonated PEG, isocyanated PEG, such as methoxy PEG-succinimidyl lower Fatty acid esters, special Succinimidyl-propionate-esterified methoxy PEG (mPEG-SPA) or succinimid
- a PEG derivative that has been subjected to maleimidation, vinylsulfonation, orthopyridyl disulfide, or odoacetamidation can also be used. These can be used to attach PEG to a PTH derivative that has a cysteine residue added to or substituted with a cysteine residue at the end of PTH or in the amino acid sequence, and the PEG binding site can be specified. .
- a method for attaching PEG to a protein in which a cysteine residue is added to or substituted with a cysteine residue a method described in Japanese Patent Application Laid-Open No.
- PEG-bound PTH or PEG-bound PTH derivative of the present invention obtained by these methods has, for example, 1 to 4 molecules of PEG bound per PTH or PTH derivative molecule.
- Mono-methoxy PEG-PTH (mono-mPEG-PTH) has one molecule of PEG bound to one molecule of PTH or PTH derivative.
- [C ys 35] - PTH (1 - 3 5) when coupling the PEG to the C-terminus of, as compared with the case of randomly bonded to P EG in Amino group activity (e.g. ⁇ vitro c AMP Sanseino)
- the quality e.g, quality standard
- £ 0 binds to Lys at the 1 ⁇ end, or at positions 13, 26, or 27.
- PEG-bound PTH produced without controlling the binding position is more active in vivo and in vitro (cells that do not overexpress the PTH receptor) than those bound at the C-terminus. Tends to decrease slightly (data not shown).
- the molecular weight of the PEG used for the modification can be appropriately changed depending on the degree of the effect of maintaining the drug effect and the degree of side effects required for the obtained PEG-bound PTH and the like, and the degree of reduction of the PTH activity.
- the molecular weight of the molecule is 1 kDa or more and less than 20 kDa, preferably 1 kDa or more and 5 kDa or less, more preferably 2 kDa or more and 5 kDa or less, particularly 2 kDa.
- PEG can be used not only in a linear form but also in a branched form or a star form.
- PEG is bound at one or more sites in PTH or PTH derivatives, preferably at 1 to 4 sites.
- the binding site is not particularly limited.
- PEG is bound to a site other than the N-terminal, for example, 9-C-terminal, 11-C-terminal, 14-. It binds to the terminal, 20- ⁇ terminal or 28-C terminal, especially to the C terminal. So far, PTH activity has been confirmed in PTH (1 -9), PTH (1-11), PTH (1-14), and PTH (1-20) (Luck, MD. Et al "Mol. Endocrinol 1999, 13, 670-680; Shimizu, M. et al "J. bio. Chem.
- a PEG binding site may be introduced into PTH or a PTH derivative, and PTH may be bound via the PEG binding site.
- the PEG binding site contains a cysteine residue.
- PEG dextran two-phase partitioning For purification of PEG-bound PTH and the like, PEG dextran two-phase partitioning, gel filtration chromatography, ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography, affinity chromatography and the like can be used.
- Example 1 shows a preparation example of PTH to which PEG having a molecular weight of 2 k, 5 k and 20 kDa is bound, that is, 2 k PEG-PTH, 5 k PEG-PTH and 20 k PEG-PTH.
- Example 2 demonstrates that these PEG-conjugated PTH retain the ability to produce cAMP, one of the PTH activities.
- these PEG-bound PTHs not only show a change in blood concentration according to the molecular weight of PEG, but also Reveals a significant improvement over PTH without PEG.
- the effect of increasing blood calcium concentration which is a problem as a side effect, is not significantly different from PTH that does not bind PEG at 2k and 5k PEG-PTH, but 20k PEG-PTH
- the effect of increasing blood calcium concentration is strong, and the increased blood calcium concentration tends to last for a long time.
- PEG-conjugated PTH to which PEG of 5 kDa or less is bound is obtained from the Fc domain of WO 01/81415. Reveal that it is safer than PTH with conjugated in. We also show that 5k PEG-PTH behaves slightly differently than PTH, which has a normal bone mass increasing effect.
- Example 6 demonstrates that PTH having 2 kDa PEG bound thereto by controlling the PEG binding position has an effect of increasing bone density.
- the present invention provides a PEG-bound PTH composition containing the above-mentioned PEG-bound PTH or PEG-bound PTH derivative, and an effective amount of the PEG-bound PTH or the PEG-bound PTH derivative in an amount effective to maintain the efficacy.
- a PEG-bound PTH composition containing the above-mentioned PEG-bound PTH or PEG-bound PTH derivative, and an effective amount of the PEG-bound PTH or the PEG-bound PTH derivative in an amount effective to maintain the efficacy.
- PEG-conjugated PTH or PEG-conjugated PTH derivative of the present invention for example, mono-methoxy PEG-PTH
- high BA facilitates control of drug efficacy and side effects, and suppresses side effects caused by lowering of blood pressure due to PTH administration.
- safe and effective treatment for osteoporosis can be achieved without excessive increase in blood calcium concentration. Therefore, it reduces or eliminates physical and mental distress caused by side effects such as headaches and nausea that patients who require long-term administration of PTH can reduce the quality of life of patients.
- QOL can be improved. Providing less painful and more effective treatments will improve patient compliance with treatment, reduce the number of fractures due to osteoporosis, and reduce the cost of geriatric care.
- One derivative can be administered, for example, once a day by subcutaneous injection, or once or twice a week.For example, once a day for subcutaneous injection, the dosage can be, for example, 1 to 1 per person for an adult. 200 g, preferably 5-100M g, more preferably 5-50 g.
- the PEG-conjugated PTH or PEG-conjugated PTH derivative according to the present invention can be administered to a patient by an administration route such as subcutaneous injection, intravenous injection, transmucosal administration (for example, transpulmonary or nasal administration), or transdermal administration. it can.
- an administration route such as subcutaneous injection, intravenous injection, transmucosal administration (for example, transpulmonary or nasal administration), or transdermal administration. it can.
- the PTH preparation of the present invention can provide a more stable preparation than conventional PTH or a PTH derivative, and is therefore more useful than the conventional one.
- Example 1 The present invention will be described in more detail with reference to the following experimental examples, but the present invention is not limited thereto.
- Example 1
- the solvent mixture of mPEG 5k-SPA and PTH was subjected to solvent exchange through PD-10 equilibrated with 20 mM acetate buffer (pH 4.0) before being subjected to cation exchange chromatography.
- the conditions of the cation exchange chromatography are shown below.
- FIG. 1a was subjected to SDS-PAGE for 2k PEG-PTH using PhastGel High Density (FIG. 1b), followed by silver staining.
- Lane M shows molecular weight markers (2512, 6214, 8159, 10700, 14404, 16949 Da)
- Lane P shows unreacted PTH
- Lane 1 shows mono-20k PEG-PTH
- Lane 2 shows cation exchange
- Lane 3 shows the mono-5k PEG-PTH reaction mixture before the chromatography
- Lane 4 shows the 5k PEG-PTH reaction mixture before the cation exchange chromatography.
- Lane 5 shows the 2k PEG-PTH reaction mixture before being subjected to cation exchange chromatography
- Lane 6 shows mono-2k PEG-PTH
- Lane 7 shows the mono- and di-2k PEG-PTH mixed fraction.
- Lane 8 represents di-2k PEG-PTH.
- lane M shows molecular weight marker
- lane P shows unreacted PTH
- lane 1 shows 5k PEG-PTH reaction mixture before subjecting to cation exchange chromatography
- lane 2 shows mono-5k PEG-PTH
- Lane 3 represents di-5k PEG-PTH
- lane 4 represents tri_5k PEG-PTH.
- HKRK-B 7 cells and HK RK-B 64 cells which are cells in which human PTH 1 receptor is genetically overexpressed in LLC-PK 1 cells, which are cells derived from bush kidney, (human PTH 1 cells per cell) about 1 X 1 0 6 or receptor, respectively, and 9 X 1 0 4 or expression), and EW2 9 (about 1 to 1 cell per rat PTH 1 receptor. 9 X 1 0 5 or expression) (Takasu et al., J Bone. Miner. Res.
- hPTH 50 ⁇ l each of hPTH (1-34) adjusted to each concentration with a binding buffer and PEG-PTH prepared in Example 1 were added, and the cells were placed in a 37: water bath and left for 20 minutes. After removing the reaction solution and placing the plate on dry ice in powder form to freeze the cells, remove the plate from the dry ice and add 50 ⁇ of 50 mM HC1 to thaw the cells. The cells were frozen again on dry ice. The amount of cAMP in the cells was measured using a commercially available EIA kit (Biotrak cAMP EIA system, manufactured by Amersham).
- Table 1 shows the cAMP producing ability of hPTH (1-34) and each PEG-PTH (1-34) molecule in HKRK_B7 cells.
- EC of 20k PEG-hPTH (1-34) 5 The value was 11 nM, indicating that cAMP production ability was reduced, but activity was retained.
- human PTH 1 receptor is less HKRK- in B 64 cells EC 5 of (2), hPTH (1-34) .
- EC 5 for 2k and 5k PEG- [Cys 35 ] -hPTH (1-35) whereas the value was 0.3 nM.
- the values were 0.6 nM and 1.0 nM, respectively, and the ability to produce cAMP was not significantly reduced.
- EC 5 of 20k PEG- [Cys 35 ] -hPTH (1-35) The value was 8.0 nM, and a decrease in CAMP production ability was observed.
- the dosing solution was administered at a dose of 1 mL / kg via a polyethylene tube inserted into the femoral vein, before administration, and 5, 15, 30, 45 minutes after administration, and 1, 2, 4, 6 Blood was collected from polyethylene tubes inserted into the femoral artery at 8, 24 hours. Subcutaneous administration was performed using rats in which a polyethylene tube was inserted into the femoral artery. The administration solution was administered at a dose of 1 mL / kg subcutaneously to the back of the rat, and blood was collected as in the case of intravenous administration. Plasma obtained by centrifugation of blood was stored at ⁇ 40 ° C. until the concentration of PTH (1-34) or PEG-PTH (1-34) was measured.
- the concentration of PTH (1-34) or PEG-PTH (1-34) was measured by the RIA method using Rat PTH IRMA Kit (manufactured by I Utopics). The radioactivity was measured using a Cobra Quantum 5005-type gamma-one counter (Packard). Plasma PTH (1-34) or PEG-PTH (1-34) concentrations were calculated using a calibration curve generated using PTH (1-34) or PEG-PTH (1-34). . The time course of the concentration of PTH (1-34) or PEG-PTH (1-34) in the obtained plasma was analyzed using Winnonlin (Ver.
- PEG-PTH 1-34
- hPTH (1-34) was diluted with 25 mmol / L phosphate citrate buffer / 00 mmol / L NaCl / 0.05% Tween 80 solution (pH 5.0) to obtain 100, 30, and 10 nmol / mL.
- Tween 80 solution pH 5.0
- 2k and 5k PEG-PTH (1-34) were similarly prepared at 30 nmol / mL (equivalent to PTH) and left on ice just before administration.
- the weight of a 5-week-old male BDF1 mouse (Nippon Charles River Co., Ltd.) was measured. Immediately before drug administration, blood was collected from the orbital heparin-coated capillaries, and blood ionized calcium concentration and PH before drug administration were measured using a Ca 2 + Z pH meter (Novaier Medical, Type 348). The measurement was performed to obtain a corrected ionized calcium concentration at a pH of 7.4.
- hPTH In the buffer group, the ionized calcium concentration gradually decreased, but hPTH (1-34) showed the largest increase in blood ionized calcium at 3 hours after administration at all doses, and then decreased. On the other hand, the change in blood ionized calcium concentration of 150 nmol / kg of 5k PEG-PTH (1-34) gradually increased after administration, and 500 nmol / kg of hPTH (1-
- the maximum value was about the same as that of 34) and tended to persist thereafter.
- PEG-PTH a blood calcium concentration increasing effect of PEG-PTH (1-35) in normal mice was examined by the following method. Dilute hPTH (1-34) with 25 mmol / L phosphate-citrate buffer 100 mmol / L NaCl / 0.05% Tween 80 solution (pH 5.0) to obtain 100, 30, and 10 nmol / mL. Was prepared. 2k, 5k and 20k PEG- [Cys 35 ] -PTH (1-35) were similarly prepared at 30, 10, and 2 nmol / mL (equivalent to PTH), and left on ice just before administration.
- a corrected ionized calcium concentration at pH 7.4 was obtained in the same manner as in (1) above.
- the buffer was 5 animals per group, 500 nmol / kg hPTH (1-34) was 4 animals per group, 150 and 50 nmol / kg hPTH (1-34) was 5 animals per group, and 150 nmol / k 2k, 5k and 20k PEG- [Cys 35 ] -PTH (1-
- the concentration of ionized calcium in the group administered with the buffer slightly changed over time, but no significant change was observed.
- hPTH (1-34) increased 1 hour after administration, reached a maximum 3 hours after administration, and then decreased.
- 2k and 5k PEG- [Cys 35 ] -PTH (1-35) showed the largest increase in blood ionized calcium concentration 3 hours after administration, and continued to decrease until 6 hours.
- 20k PEG- [Cys 35 ] -PTH (1-35) showed a high value at 3 hours after administration, and a clearly higher value at 9 hours after administration than in the buffer administration group.
- the 20 k PEG- [Cys 35 ] -PTH (1-35) administration group showed a very high blood ionization ability at all doses. It was clear that the patient had hypercalcemia.
- hPTH (1-34) (Peptide Laboratories) was prepared at 2.5 mg / mL with 25 mM phosphate citrate buffer and stored frozen at -20 ° C or lower until use. On the day of the test, dilute 2.5 mg / mL hPTH (1-34) with 25 mM phosphoric acid-citrate buffer / ⁇ OO mM NaClZO.05% Tween 80 solution (pH 5.0) to obtain 50, 25 and 12.5 g. / mL.
- Mono-methoxy 5k PEG-PTH (1-34) prepared in Example 1 (2) was also prepared at 36.5, 18.3 and 9.1 g / mL (corresponding to PTH (1-34)). After preparation, the solution was stored on ice and returned to room temperature about 30 minutes before administration.
- a 10-week-old female SD rat (Nippon Charles River Co., Ltd.) was anesthetized with intraperitoneal injection (50 mg / kg) of sodium pentobarbital (Abbott Laboratories), and a catheter for blood pressure measurement was placed in the femoral artery.
- a catheter for blood pressure measurement was placed in the femoral artery.
- a maintenance anesthesia force was used for maintenance anesthesia, and sodium pentobarbital dissolved in physiological saline (Otsuka Pharmaceutical Co., Ltd.)
- the blood pressure measurement catheter was filled with heparin sodium (Nopo-Nordisk A / S) diluted to 100 U / mL with physiological saline.
- the systemic blood pressure was measured by inputting a signal from a pressure transducer (Nihon Kohden Corporation) attached to a blood pressure measurement catheter to a blood pressure amplifier (Nihon Kohden Corporation) and using the average blood pressure as an index.
- Heart rate was measured by inputting the output of whole-body blood pressure to an instantaneous heart rate unit (Nihon Kohden Corporation).
- the above parameters are the thermal pen type recorder
- FIG. 6 shows a representative example of the change over time in blood pressure up to 20 minutes after administration.
- a negative control substance (buffer), 50 g / kg hPTH (1 -34), 36.5 g / kg 5k PEG-PTH (1 -34)
- the blood pressure change when administered is shown.
- the mean blood pressure value before PTH administration and the value indicating the decrease in systolic blood pressure after administration were measured, and the difference between the mean blood pressure value and the decrease in systolic blood pressure was determined.
- Figure 7 shows the results as the average soil standard error.
- the vertical axis indicates the maximum blood pressure drop (Hg), and the horizontal axis indicates the dose of PTH.
- the solids indicate the buffer solution, the analogy indicates hPTH (Table 34), and the symbol ⁇ indicates the 5k PEG-PTH (Table 34).
- hPTH-344 shows a strong blood pressure lowering effect immediately after administration, whereas 5k PEG-PTH (1-
- hPTH shows a blood pressure-lowering effect from 12.5 g / kg to 50 ⁇ g / g in a dose-dependent manner
- 5k PEG-PTH has a weak blood pressure-lowering effect, In particular, it was shown to be very weak as compared with the high dose bapa and hPTH (1-34) (Fig. 7).
- the buffer was administered to the 7 sham-operated groups, and the buffer, hPTH (l-34), [Cys 35 ] -hPTH (1-35) (10 , 2.5 and 0.625 nmol / kg), 2k PEG- [Cys 35 ] -PTH (1-35) (120, 30 and 7.5 nmol / kg) was administered respectively.
- the dose was 1 ml / kg, and subcutaneous administration was performed 5 times a week for 4 weeks.
- Rats were placed in metabolic cages on the last day of administration and urine was collected for 24 hours.On the day after the last day of administration, rats were euthanized by exsanguination under anesthesia, necropsy was performed, and blood, lumbar spine and femur were collected did. Urine and blood were collected in tubes and the supernatant was collected by centrifugation and stored at 1-20 until overnight measurements of the parameters. The lumbar spine and right femur were stored in 70% ethanol. The average bone density of the lumbar vertebrae (second to fifth lumbar vertebrae) and the bone density of the right femur were measured using a dual X-ray bone mineral density analyzer (DCS-600EX, Aroca).
- DCS-600EX dual X-ray bone mineral density analyzer
- FIG. 8 the mean bone density increasing effect of the waist intervertebral (a)
- Figure 8 (b) shows the effect of increasing the bone density of the right femur.
- the ovariectomized group showed a significant decrease in bone density in the lumbar spine and femur compared to the sham-operated group.
- administration of hPTH (1-34) and [Cys 35 ] -hPTH (1-35) increased bone density in the lumbar spine and femur in a dose-dependent manner, with 2.5 nmol / kg and 10 nmol / kg in the lumbar spine. Showed a significant bone mass increasing effect.
- the PEG-bound PTH or PEG-bound PTH derivative of the present invention is useful as a PTH preparation that reduces the burden on patients.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003564082A JPWO2003064462A1 (ja) | 2002-02-01 | 2003-02-03 | Peg結合pth又はpeg結合pth誘導体 |
EP03734634A EP1477496A4 (en) | 2002-02-01 | 2003-02-03 | PEG BINDING PTH OR PEG BINDING PTH DERIVATIVE |
US10/503,075 US20050148763A1 (en) | 2002-02-01 | 2003-02-03 | Peg-binding pth or peg-binding pth derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-26194 | 2002-02-01 | ||
JP2002026194 | 2002-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003064462A1 true WO2003064462A1 (fr) | 2003-08-07 |
Family
ID=27654585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001067 WO2003064462A1 (fr) | 2002-02-01 | 2003-02-03 | Pth a liaison peg ou derive de pth a liaison peg |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050148763A1 (ja) |
EP (1) | EP1477496A4 (ja) |
JP (1) | JPWO2003064462A1 (ja) |
WO (1) | WO2003064462A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006006674A1 (ja) * | 2004-07-14 | 2006-01-19 | Chugai Seiyaku Kabushiki Kaisha | Pthを含有する経粘膜投与剤 |
JP2007003256A (ja) * | 2005-06-22 | 2007-01-11 | Techno Medica Co Ltd | 腎臓機能コントロール状態測定方法及び測定システム |
US8106131B2 (en) | 2002-12-31 | 2012-01-31 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
JP2019533649A (ja) * | 2016-09-29 | 2019-11-21 | アセンディス ファーマ ボーン ディジージズ エー/エス | 放出制御pth化合物の漸増用量設定 |
WO2020165087A1 (en) | 2019-02-11 | 2020-08-20 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of pth conjugates |
US11590207B2 (en) | 2016-09-29 | 2023-02-28 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release PTH compound |
US11759504B2 (en) | 2016-09-29 | 2023-09-19 | Ascendis Pharma Bone Diseases A/S | PTH compounds with low peak-to-trough ratios |
US11793861B2 (en) | 2016-03-01 | 2023-10-24 | Ascendis Pharma Bone Diseases A/S | PTH prodrugs |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247609B2 (en) * | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
JP2006521372A (ja) * | 2003-03-28 | 2006-09-21 | バイオポリメド インコーポレーテッド | 生物学的活性物質と生体適合性高分子の1:1接合体、この製造方法とこれを含む薬学組成物 |
MX2007015819A (es) * | 2005-06-13 | 2008-02-22 | Nastech Pharm Co | Suministro de derivados peptidicos a traves de la mucosa. |
EP1945245A2 (en) * | 2005-11-10 | 2008-07-23 | The Board of Control of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
SI2084183T1 (sl) * | 2006-10-13 | 2010-09-30 | Lilly Co Eli | Pegilirani pth kot modulatorji pth receptorja in njihove uporabe |
JP2012512812A (ja) * | 2007-12-28 | 2012-06-07 | クロス・バイオサージェリー・アクチェンゲゼルシャフト | フィブリンフォームに組込まれたpdgf融合タンパク質 |
US8987201B2 (en) | 2009-12-07 | 2015-03-24 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
US20130143797A1 (en) | 2010-06-25 | 2013-06-06 | Michael J. Tisdale | Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof |
CA2879250A1 (en) * | 2012-07-31 | 2014-02-06 | Aston University | Targeted oesophageal administration of zn-.alpha.2-glycoproteins (zag), methods and formulations thereof |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07196925A (ja) * | 1992-12-09 | 1995-08-01 | Ortho Pharmaceut Corp | Pegヒドラゾンおよびpegオキシム結合形成試薬およびそれらのタンパク質誘導体 |
WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
WO2001081415A2 (en) * | 2000-04-27 | 2001-11-01 | Amgen Inc. | Parathyroid hormone and parathyroid hormone-related protein antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
NZ509238A (en) * | 1998-07-27 | 2003-07-25 | Emisphere Tech Inc | Pulmonary delivery of active agents the carrier containing acylated or sulfonated amino acids |
KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
-
2003
- 2003-02-03 EP EP03734634A patent/EP1477496A4/en not_active Ceased
- 2003-02-03 JP JP2003564082A patent/JPWO2003064462A1/ja active Pending
- 2003-02-03 US US10/503,075 patent/US20050148763A1/en not_active Abandoned
- 2003-02-03 WO PCT/JP2003/001067 patent/WO2003064462A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07196925A (ja) * | 1992-12-09 | 1995-08-01 | Ortho Pharmaceut Corp | Pegヒドラゾンおよびpegオキシム結合形成試薬およびそれらのタンパク質誘導体 |
WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
WO2001081415A2 (en) * | 2000-04-27 | 2001-11-01 | Amgen Inc. | Parathyroid hormone and parathyroid hormone-related protein antagonists |
Non-Patent Citations (2)
Title |
---|
See also references of EP1477496A4 * |
TSUTSUMI Y. ET AL.: "Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency", JPN. J. CANCER RES., vol. 85, no. 1, 1994, pages 9 - 12, XP002913448 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106131B2 (en) | 2002-12-31 | 2012-01-31 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
US8227555B2 (en) | 2002-12-31 | 2012-07-24 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
US8835556B2 (en) | 2002-12-31 | 2014-09-16 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
WO2006006674A1 (ja) * | 2004-07-14 | 2006-01-19 | Chugai Seiyaku Kabushiki Kaisha | Pthを含有する経粘膜投与剤 |
JPWO2006006674A1 (ja) * | 2004-07-14 | 2008-05-01 | 中外製薬株式会社 | Pthを含有する経粘膜投与剤 |
JP2007003256A (ja) * | 2005-06-22 | 2007-01-11 | Techno Medica Co Ltd | 腎臓機能コントロール状態測定方法及び測定システム |
JP4633552B2 (ja) * | 2005-06-22 | 2011-02-16 | 株式会社テクノメディカ | 腎臓機能コントロール状態測定方法及び測定システム |
US11793861B2 (en) | 2016-03-01 | 2023-10-24 | Ascendis Pharma Bone Diseases A/S | PTH prodrugs |
US11759504B2 (en) | 2016-09-29 | 2023-09-19 | Ascendis Pharma Bone Diseases A/S | PTH compounds with low peak-to-trough ratios |
JP7039574B2 (ja) | 2016-09-29 | 2022-03-22 | アセンディス ファーマ ボーン ディジージズ エー/エス | 放出制御pth化合物の漸増用量設定 |
JP2022081604A (ja) * | 2016-09-29 | 2022-05-31 | アセンディス ファーマ ボーン ディジージズ エー/エス | 放出制御pth化合物の漸増用量設定 |
US11590207B2 (en) | 2016-09-29 | 2023-02-28 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release PTH compound |
JP2019533649A (ja) * | 2016-09-29 | 2019-11-21 | アセンディス ファーマ ボーン ディジージズ エー/エス | 放出制御pth化合物の漸増用量設定 |
US11857603B2 (en) | 2016-09-29 | 2024-01-02 | Ascendis Pharma Bone Diseases A/S | PTH compounds with low peak-to-trough ratios |
US11890326B2 (en) | 2016-09-29 | 2024-02-06 | Ascendis Pharma Bone Diseases A/S | Controlled-release PTH compound |
US11918628B2 (en) | 2016-09-29 | 2024-03-05 | Ascendis Pharma Bone Diseases A/S | Controlled-release PTH compound |
WO2020165087A1 (en) | 2019-02-11 | 2020-08-20 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of pth conjugates |
Also Published As
Publication number | Publication date |
---|---|
EP1477496A4 (en) | 2006-08-02 |
EP1477496A1 (en) | 2004-11-17 |
JPWO2003064462A1 (ja) | 2005-05-26 |
US20050148763A1 (en) | 2005-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003064462A1 (fr) | Pth a liaison peg ou derive de pth a liaison peg | |
JP4689833B2 (ja) | グルカゴン様ペプチド−1の貯蔵安定性製剤 | |
KR100345214B1 (ko) | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 | |
CN102026666B (zh) | 促胰岛素肽缀合物制剂 | |
KR101352225B1 (ko) | 신규한 엑센딘 변형 및 이들의 콘쥬게이트 | |
TW434259B (en) | Acylated insulin analogs | |
ES2215268T3 (es) | Soluciones de teriparatide estabilizadas. | |
RU2467762C2 (ru) | Составы паратиреоидного гормона и их применение | |
ZA200602000B (en) | Albumin-binding derivatives of therapeutic peptides | |
EP3689365A1 (en) | Use of long-acting glp-1 peptides | |
AU2004298424A1 (en) | Novel GLP-1 compounds | |
JP2005537232A (ja) | アミリンアゴニストペプチドの製剤 | |
EP2512450B1 (en) | Dry growth hormone composition transiently linked to a polymer carrier | |
WO1996029342A1 (en) | Lipophilic peptide hormone derivatives | |
KR20110114568A (ko) | 디펩티드 링크된 약효 물질 | |
EA004791B1 (ru) | Композиции на основе слитого белка ob и способы их применения | |
EP3351561A1 (en) | Long-acting adrenomedullin derivative | |
EP2945643A1 (en) | Therapeutic agents, compositions, and methods for glycemic control | |
CN110603260B (zh) | Npra激动剂、组合物及其用途 | |
CN101912600A (zh) | 改善胰岛素在溶液中稳定性的方法 | |
AU2017361524B2 (en) | Rapid-acting insulin analogues of enhanced stability | |
CN103328006A (zh) | 包含胰岛素、烟酰胺和氨基酸的制剂 | |
TW202136289A (zh) | 新穎之胰島素類似物及其用途 | |
EP1600162A1 (en) | Shelf-stable formulation of glucagon-like peptide-1 | |
JP6005732B2 (ja) | 非ペプチド性重合体−インスリン多量体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003564082 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003734634 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003734634 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10503075 Country of ref document: US |